Building on this, the PETRARCA study delved into the perioperative clinical efficacy of integrating anti-Her2 dual-target treatment with FLOT chemotherapy, compared to FLOT alone, in patients with cT2-4 and/or N+ G/GEJ adenocarcinoma and HER2 overexpression. The gene discussed is ERBB2; the disease is adenocarcinoma.